CrownBio’s world-leading products and services are used by pharmaceutical and biotech customers across APAC, North America, and Europe to accelerate and de-risk their drug discovery programs.
Under the agreement, Igyxos will utilize Selexis’ proprietary SUREtechnology Platform™ to rapidly develop the research cell banks (RCBs) necessary to advance the program to human trials.
The MEBCDX AAV9 test kit was therefore developed as a CDx to be used as an aid in selecting anti-AAV9 antibody negative SMA patients for treatment with Zolgensma.
1 of 2
Receive JSR Life Sciences news on your RSS reader.